Summary of Nuvation Bio's Q3 2025 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $13.1 million, with $7.7 million in net product revenue from IBTROZI.

New Patient Starts: 204 new patients began treatment with IBTROZI in Q3, averaging over 15 new starts per week.

Gross to Net Revenue: Approximately 20%, expected to increase slightly over time.

Cash Position: $549 million in cash, cash equivalents, and marketable securities, with an additional $50 million available under a term loan.

Operating Expenses: R&D expenses were $28.8 million, and SG&A expenses were $37.4 million, primarily for commercialization efforts.

2Strategic Updates and Business Highlights

IBTROZI Launch: The launch is progressing well, with strong physician support and a growing patient base. The company aims to establish IBTROZI as the new standard of care for ROS1-positive non-small cell lung cancer.

Clinical Data: Updated data shows a median duration of response (DOR) of 50 months for TKI-naive patients, reinforcing IBTROZI's efficacy and safety profile.

Expansion Plans: Initiated the TRUST-IV study for IBTROZI as adjuvant therapy in early-stage non-small cell lung cancer. Regulatory approval received in Japan, with expectations for reimbursement approval leading to a $25 million milestone payment.

Pipeline Development: Progress on safusidenib for IDH1-mutant glioma, with plans for a pivotal Phase III study.

3Forward Guidance and Outlook

Patient Growth: Anticipated continued growth in patient starts, with expectations for a significant increase in first-line patient adoption as awareness and testing improve.

Revenue Projections: While not providing specific revenue guidance, management indicated comfort with current consensus estimates for 2026 at approximately $115 million, driven by the long DOR of IBTROZI.

Market Expansion: Plans to finalize a European commercialization partnership in Q4, which could enhance revenue streams.

4Bad News, Challenges, or Points of Concern

Competitive Landscape: Concerns about upcoming competitors entering the market, although management expressed confidence in IBTROZI's unique efficacy metrics compared to existing therapies.

Market Access: Although payer engagement is strong, the company must continue to navigate the complexities of reimbursement and coverage, particularly in new markets.

Long Study Timelines: The Phase III study for safusidenib is expected to take several years to complete, with data not anticipated until 2029, which may limit short-term visibility.

5Notable Q&A Insights

Sales Guidance: Management refrained from providing specific sales guidance but noted strong performance in Q3 as a positive indicator for future growth.

Patient Demographics: Acknowledged that the majority of new patients are currently coming from academic centers, with expectations for more community-based patient starts as awareness grows.

Market Share: While difficult to quantify due to data limitations, management believes they are capturing a significant share of the market, outperforming competitors in early launch metrics.

Expanded Access Program: Very few patients transitioned from the expanded access program to commercial treatment, indicating that most patients are new diagnoses. Overall, Nuvation Bio's Q3 2025 results reflect a strong start for IBTROZI's commercial launch, with promising clinical data and strategic initiatives aimed at expanding market presence, despite facing competitive pressures and the challenges of navigating the healthcare landscape.